-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier: European Commission Approves Novartis' Rhapsido For Chronic Spontaneous Urticaria In Adult Patients With Inadequate Response To H1-Antihistamine Treatment

Benzinga·04/27/2026 16:13:59
Listen to the news

Novartis announced today that the European Commission (EC) approved Rhapsido® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment. Rhapsido is the first oral targeted treatment approved for CSU, offering a unique approach to CSU treatment in a pill taken twice daily without any lab monitoring required1.